HRP20201152T1 - Kondenzirani benzazepin za liječenje mucanja - Google Patents
Kondenzirani benzazepin za liječenje mucanja Download PDFInfo
- Publication number
- HRP20201152T1 HRP20201152T1 HRP20201152TT HRP20201152T HRP20201152T1 HR P20201152 T1 HRP20201152 T1 HR P20201152T1 HR P20201152T T HRP20201152T T HR P20201152TT HR P20201152 T HRP20201152 T HR P20201152T HR P20201152 T1 HRP20201152 T1 HR P20201152T1
- Authority
- HR
- Croatia
- Prior art keywords
- selective
- receptor antagonist
- antagonist
- use according
- ecopipam
- Prior art date
Links
- 208000003028 Stuttering Diseases 0.000 title claims 6
- 150000008038 benzoazepines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 claims 34
- 229940044551 receptor antagonist Drugs 0.000 claims 34
- 239000005557 antagonist Substances 0.000 claims 10
- DMJWENQHWZZWDF-PKOBYXMFSA-N (6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol Chemical compound CN1CCC2=CC(Cl)=C(O)C=C2[C@H]2C3=CC=CC=C3CC[C@H]12 DMJWENQHWZZWDF-PKOBYXMFSA-N 0.000 claims 7
- 229950009714 ecopipam Drugs 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000001107 psychogenic effect Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (17)
1. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u liječenju mucanja.
2. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s patentnim zahtjevom 1, pri čemu je subjekt muškarac ljudskog roda.
3. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s patentnim zahtjevom 1 ili 2, pri čemu subjekt nije stariji od 17 godina.
4. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu se za subjekta smatra da ne boluje od poremećaja pažnje s hiperaktivnošću, depresije, Touretteovog sindroma i opsesivno-kompulzivnog poremećaja.
5. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1 do 4, pri čemu je mucanje povezano s poremećajem razvojnog mucanja.
6. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s bilo kojim od 1 patentnih zahtjeva 1 do 4, pri čemu je mucanje povezano s neurogenim ili psihogenim poremećajem.
7. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, 5 ili 6 , pri čemu antagonist sadrži ekopipam odnosno sol, solvat, hidrat, prolijek, strukturni analog ili polimorf ekopipama koji su farmaceutski prihvatljivi.
8. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu sa patentnim zahtjevom 7, pri čemu antagonist sadrži ekopipam ili farmaceutski prihvatljivu sol ekopipama.
9. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1-3, ili 5-8, pri čemu je formula antagonista namijenjena oralnoj primjeni.
10. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s patentnim zahtjevima 8 ili 9 pri čemu antagonist sadrži ekopipam ili farmaceutski prihvatljivu sol ekopipama i formula je primjerena za doziranje 1 mg/kg tjelesne težine dnevno.
11. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s patentnim zahtjevima 8 ili 9 pri čemu antagonist sadrži ekopipam ili farmaceutski prihvatljivu sol ekopipama i formula je primjerena za doziranje 2 mg/kg tjelesne težine dnevno.
12. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s patentnim zahtjevom 9, pri čemu je formula antagonista primjerena za doziranje oko 0,01 mg/kg do oko 500 mg/kg i pri čemu se doza prilagođava ovisno o dobi i tjelesnoj težini.
13. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s patentnim zahtjevom 12, pri čemu je formula antagonista primjerena za doziranje oko 0,01 mg/kg do oko 50 mg/kg; oko 0,01 mg/kg do oko 5 mg/kg; ili oko 0,1 mg/kg do oko 5 mg/kg.
14. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s patentnim zahtjevom 12, pri čemu je formula antagonista primjerena za doziranje od 5 do 100 mg/dan.
15. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1-3, ili 5-14, pri čemu je formula antagonista primjerena za doziranje jedanput dnevno.
16. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1-3, ili 5-15, pri čemu je antagonist namijenjen primjeni uz drugu liniju liječenja poremećaja mucanja.
17. Selektivni antagonist D1-receptora i/ili selektivni antagonist D5-receptora za upotrebu u skladu sa patentnim zahtjevom 16, pri čemu drugu liniju liječenja čini bihevioralna, kirurška ili farmaceutska terapija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892841P | 2013-10-18 | 2013-10-18 | |
| EP14854586.6A EP3057595B1 (en) | 2013-10-18 | 2014-10-17 | Fused benzazepines for treatment of stuttering |
| PCT/US2014/061080 WO2015058053A1 (en) | 2013-10-18 | 2014-10-17 | Fused benzazepines for treatment of stuttering |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201152T1 true HRP20201152T1 (hr) | 2020-10-30 |
Family
ID=52828726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201152TT HRP20201152T1 (hr) | 2013-10-18 | 2020-07-23 | Kondenzirani benzazepin za liječenje mucanja |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9949983B2 (hr) |
| EP (1) | EP3057595B1 (hr) |
| JP (3) | JP2016533374A (hr) |
| AU (1) | AU2014337140B2 (hr) |
| CA (1) | CA2927915C (hr) |
| CY (1) | CY1123121T1 (hr) |
| DK (1) | DK3057595T3 (hr) |
| ES (1) | ES2805448T3 (hr) |
| HR (1) | HRP20201152T1 (hr) |
| HU (1) | HUE049848T2 (hr) |
| IL (1) | IL245155B (hr) |
| LT (1) | LT3057595T (hr) |
| MX (1) | MX370612B (hr) |
| PL (1) | PL3057595T3 (hr) |
| PT (1) | PT3057595T (hr) |
| RS (1) | RS60556B1 (hr) |
| SI (1) | SI3057595T1 (hr) |
| WO (1) | WO2015058053A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014012034A1 (en) | 2012-07-12 | 2014-01-16 | Psyadon Pharmaceuticals, Inc. | Fused benzazepines for treatment of tourette's syndrome |
| BR112019019242A2 (pt) | 2017-03-30 | 2020-04-14 | Jose Eduardo Penello Temporao | composição multivitamínica para aprimoramento da fluência verbal, dimimuição dos sintomas da ansiedade de performance e seu método e preparação |
| AU2018274765A1 (en) * | 2017-05-25 | 2020-01-23 | Glytech Llc. | Formulations for treatment of post-traumatic stress disorder |
| US10786495B2 (en) * | 2017-10-10 | 2020-09-29 | The Regents Of The University Of California | Vesicular monoamine transporter 2 inhibitors for treating stuttering |
| EP3972573A4 (en) * | 2019-05-23 | 2023-07-12 | India Globalization Capital, Inc. | COMPOSITIONS AND METHODS USING CANNABINOIDS FOR TREATING STUTTERING AND SYMPTOMS OF TOURETTE SYNDROME |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4477378A (en) | 1980-02-05 | 1984-10-16 | Schering Corp. | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines |
| US5302716A (en) | 1986-01-16 | 1994-04-12 | Schering Corporation | Fused benzazepines |
| US4973586A (en) | 1986-01-16 | 1990-11-27 | Schering Corporation | Fused benzazepines, compositions of, and medical use thereof |
| BE1005064A4 (nl) | 1991-07-03 | 1993-04-06 | Asm Fico Tooling | Buiginrichting. |
| GB9127306D0 (en) | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
| DE69521122T2 (de) | 1994-03-16 | 2002-03-07 | Cenes Ltd | 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze |
| KR20010031470A (ko) * | 1997-10-28 | 2001-04-16 | 둘락 노먼 씨. | 포유동물의 갈망을 감소시키는 방법 |
| US6132724A (en) * | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| US8518933B2 (en) * | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2012033874A1 (en) * | 2010-09-10 | 2012-03-15 | Chipkin Richard E | Method of treating compulsive self-injurious behaviors |
| WO2014012034A1 (en) | 2012-07-12 | 2014-01-16 | Psyadon Pharmaceuticals, Inc. | Fused benzazepines for treatment of tourette's syndrome |
-
2014
- 2014-10-17 RS RS20200880A patent/RS60556B1/sr unknown
- 2014-10-17 PT PT148545866T patent/PT3057595T/pt unknown
- 2014-10-17 WO PCT/US2014/061080 patent/WO2015058053A1/en active Application Filing
- 2014-10-17 EP EP14854586.6A patent/EP3057595B1/en active Active
- 2014-10-17 ES ES14854586T patent/ES2805448T3/es active Active
- 2014-10-17 DK DK14854586.6T patent/DK3057595T3/da active
- 2014-10-17 PL PL14854586T patent/PL3057595T3/pl unknown
- 2014-10-17 CA CA2927915A patent/CA2927915C/en active Active
- 2014-10-17 SI SI201431621T patent/SI3057595T1/sl unknown
- 2014-10-17 JP JP2016524108A patent/JP2016533374A/ja not_active Withdrawn
- 2014-10-17 MX MX2016005030A patent/MX370612B/es active IP Right Grant
- 2014-10-17 LT LTEP14854586.6T patent/LT3057595T/lt unknown
- 2014-10-17 HU HUE14854586A patent/HUE049848T2/hu unknown
- 2014-10-17 US US15/030,271 patent/US9949983B2/en active Active
- 2014-10-17 AU AU2014337140A patent/AU2014337140B2/en active Active
-
2016
- 2016-04-17 IL IL245155A patent/IL245155B/en active IP Right Grant
-
2019
- 2019-06-13 JP JP2019110259A patent/JP7245509B2/ja active Active
-
2020
- 2020-07-10 CY CY20201100641T patent/CY1123121T1/el unknown
- 2020-07-23 HR HRP20201152TT patent/HRP20201152T1/hr unknown
-
2021
- 2021-03-01 JP JP2021031859A patent/JP2021080288A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI3057595T1 (sl) | 2020-09-30 |
| EP3057595B1 (en) | 2020-04-29 |
| US9949983B2 (en) | 2018-04-24 |
| EP3057595A1 (en) | 2016-08-24 |
| ES2805448T3 (es) | 2021-02-12 |
| NZ719103A (en) | 2021-05-28 |
| EP3057595A4 (en) | 2017-06-07 |
| HUE049848T2 (hu) | 2020-11-30 |
| JP2019147843A (ja) | 2019-09-05 |
| PL3057595T3 (pl) | 2021-03-08 |
| WO2015058053A1 (en) | 2015-04-23 |
| JP7245509B2 (ja) | 2023-03-24 |
| CA2927915A1 (en) | 2015-04-23 |
| IL245155B (en) | 2020-07-30 |
| LT3057595T (lt) | 2020-08-10 |
| AU2014337140A1 (en) | 2016-05-12 |
| PT3057595T (pt) | 2020-07-31 |
| IL245155A0 (en) | 2016-06-30 |
| CY1123121T1 (el) | 2021-10-29 |
| AU2014337140B2 (en) | 2020-01-30 |
| JP2016533374A (ja) | 2016-10-27 |
| JP2021080288A (ja) | 2021-05-27 |
| MX370612B (es) | 2019-12-18 |
| CA2927915C (en) | 2021-10-26 |
| DK3057595T3 (da) | 2020-08-10 |
| US20160271141A1 (en) | 2016-09-22 |
| RS60556B1 (sr) | 2020-08-31 |
| MX2016005030A (es) | 2017-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201152T1 (hr) | Kondenzirani benzazepin za liječenje mucanja | |
| HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| PH12017501140A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
| HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
| JP2016501828A5 (hr) | ||
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| JP2015515475A5 (hr) | ||
| JP2016147915A5 (hr) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2012136529A5 (hr) | ||
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| JP2015532296A5 (hr) | ||
| ME02414B (me) | Tretman kronove bolesti lakvinimodom | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2010536849A5 (hr) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja | |
| IT201800001301A1 (it) | Formulazioni in gel per la somministrazione orale di farmaci, in particolare nei pazienti disfagici | |
| IL210386A (en) | Indole history, their medicinal preparations, and their use in the preparation of drugs for the treatment or prevention of neurodegenerative diseases | |
| SI2729474T1 (en) | (TIENO (2,3-b) (1,5) BENZOXAZEPIN-4-YL) PIPERAZINE-1-IL COMPOUNDS AS TWO ACTIVE H1 INVERTIVE AGENTS / 5-HT2A ANTAGONISTS |